SCHEMBL6645798

SCHEMBL6645798

O=C(Nc1ccc(OCCc2ccccn2)cc1)c1cccnc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
HTT P42858 1/20 0.51
PPARG P37231 1/20 0.51
RAB9A P51151 5/20 0.50
NPC1 O15118 5/20 0.50
ALDH1A1 P00352 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
KDM4E B2RXH2 2/20 0.50
PKM P14618 2/20 0.50
MAPT P10636 2/20 0.50
MITF O75030 1/20 0.50
GRM4 Q14833 1/20 0.49
POLB P06746 1/20 0.48
GAA P10253 1/20 0.48
ALOX15 P16050 1/20 0.48
CNR1 P21554 1/20 0.47
ATM Q13315 1/20 0.47
TSHR P16473 1/20 0.46
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6649755 0.86 PPARG (0.49) KMT2AMEN1HTTPPARGRAB9A
SCHEMBL15528742 0.81 KDM4E (0.71) KMT2AMEN1HTTPPARGRAB9A
SCHEMBL6649434 0.80 L3MBTL1 (0.68) KMT2AMEN1HTTRAB9ANPC1
SCHEMBL6645468 0.80 RAB9A (0.65) KMT2AMEN1RAB9ANPC1ALDH1A1
SCHEMBL6106989 0.79 ALDH1A1 (0.64) KMT2AMEN1HTTRAB9ANPC1
SCHEMBL6642573 0.79 MEN1 (0.49) KMT2AMEN1HTTRAB9ANPC1
SCHEMBL1499710 0.78 MAPT (0.70) KMT2AMEN1HTTPPARGRAB9A
SCHEMBL6793327 0.77 SMO (0.59) HTTALDH1A1POLBGAA
SCHEMBL6794029 0.77 MAPT (0.49) KMT2AMEN1HTTRAB9ANPC1
SCHEMBL6644178 0.77 L3MBTL1 (0.56) KMT2AMEN1RAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR KMT2A 916/4885MEN1 3820/4885HTT 1332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.